Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561087 · ClinicalTrials.gov registry record · Phase 2
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
A Phase 2 study of Premalignant Lesion, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06561087 is a Phase 2 study of Premalignant Lesion that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants, below the 232-participant average among 4 other Premalignant Lesion trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06561087, a Phase 2 study of Premalignant Lesion, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the antitumor efficacy of intralesional injections of nivolumab in patients with high-risk oral premalignant lesions
Conditions Studied
Interventions
- DRUG Nivolumab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-02-27 |
| Est. Completion | 2029-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06561087
The ClinicalTrials.gov registry entry for NCT06561087 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 4 other Premalignant Lesion trials with a reported enrollment target (81% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Premalignant Lesion appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT06561087 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06561087 about?
NCT06561087 is a clinical study titled "Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions". To evaluate the antitumor efficacy of intralesional injections of nivolumab in patients with high-risk oral premalignant lesions
What is the current status of trial NCT06561087?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-02-27. Estimated completion is 2029-05-30.
What conditions does trial NCT06561087 study?
This clinical trial studies the following conditions: Premalignant Lesion.
What interventions are being tested in trial NCT06561087?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT06561087?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561087 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premalignant Lesion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
RECRUITING
-
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
ACTIVE NOT RECRUITING · Early Phase 1
-
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
ACTIVE NOT RECRUITING · NA
-
Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.